ARCT

About ARCT

Arcturus Therapeutics Holdings Inc. is a late-stage global clinical messenger ribonucleic acid (mRNA) medicines company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The Company's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).